The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. The data will be released at the American Association of Cancer Research meeting. "We'll be the belles of the ball at AACR with this one," says Bolen, whose scientific journey started at the University of Nebraska and wound through 10 years of work at the NIH, where he won the institute's Meritorious Research for his work on protein tyrosine kinase oncogenes.
- read the profile [1] in The Scientist
Related Articles:
Millennium spent $1.3M on lobbying. Report [2]
Positive Velcade data fuels stock rise. Report [3]
Millennium to buy AnorMed for $515M. Report [4]
Links:
[1] http://www.the-scientist.com/article/display/54340/
[2] http://www.fiercebiotech.com/story/millennium-spent-1-3m-lobbying/2008-02-08
[3] http://www.fiercebiotech.com/story/spotlight-positive-velcade-data-fuels-stock-rise/2007-09-18
[4] http://www.fiercebiotech.com/story/millennium-to-buy-anormed-for-515m/2006-09-27